Analyst Price Targets — OGN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 24, 2026 10:45 am | — | Barclays | $8.00 | $7.92 | TheFly | Organon price target raised to $8 from $7.50 at Barclays |
| December 8, 2025 9:26 pm | — | Barclays | $7.50 | $7.29 | TheFly | Organon initiated with an Underweight at Barclays |
| October 27, 2025 2:55 pm | David Amsellem | Piper Sandler | $5.00 | $7.13 | TheFly | Piper double downgrades Organon to Underweight after CEO resignation |
| May 15, 2025 10:42 am | David Amsellem | Piper Sandler | $18.00 | $8.77 | TheFly | Organon price target lowered to $18 from $24 at Piper Sandler |
| May 5, 2025 11:30 am | Terence Flynn | Morgan Stanley | $10.00 | $8.72 | TheFly | Organon price target lowered to $10 from $15 at Morgan Stanley |
| April 29, 2024 7:40 am | David Amsellem | Piper Sandler | $24.00 | $18.85 | StreetInsider | Organon & Co. (OGN) PT Raised to $24 at Piper Sandler |
| June 26, 2023 9:08 am | David Amsellem | Piper Sandler | $34.00 | $20.37 | Benzinga | Check Out 3 Health Care Stocks With Over 4% Dividend Yields From Wall Street's Most Accurate Analysts |
Latest News for OGN
STOCKHOLM, Sweden, March 3, 2026. KDventures AB (Nasdaq Stockholm: KDV) today announces that Organon has discontinued the development of a preclinical drug candidate for polycystic ovarian syndrome (PCOS) that was part of the acquisition of the portfolio company Forendo. Thus, the development of both drug candidates included in the acquisition has been discontinued. KDventures will therefore write off its entire…
Organon reports Phase 3 data showing VTAMA improved sleep in children as young as two with atopic dermatitis, reinforcing its dermatology push.
VANCOUVER, BC / ACCESS Newswire / February 27, 2026 / (TSXV:OGN)(OTCQB:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce that it has signed a purchase and sale agreement (the "Agreement") with Quebec Nickel Corp. (CSE: QNI) ("Quebec Nickel") whereby Quebec Nickel can acquire a 100% interest in the Ecru gold project, Nevada, USA. Under the terms of the Agreement, Quebec Nickel can…
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon presents results from new VTAMA sub-analysis showing early and consistent improvement in atopic dermatitis patient-reported sleep subdomains.
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered into an agreement to exclusively license global rights to MIUDELLA, Sebela Pharmaceuticals' hormone-free copper intrauterine device (IUD) contraceptive. The effectiveness of this transaction is subject to review…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.